CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

emtricitabine/rilpivirine/ tenofovir alafenamide

Last Updated: October 27, 2016
Result type: Reports
Project Number: SR0507-000
Product Line: Reimbursement Review

Generic Name: emtricitabine/rilpivirine/ tenofovir alafenamide

Brand Name: Odefsey

Manufacturer: Gilead Sciences Canada, Inc.

Therapeutic Area: HIV-1 infection

Indications: HIV-1 infection

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 25, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions